Novavax | NVAX - Selling And Administration Expenses

Novavax reported $161.66M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Selling And Administration Expenses Change
Adma Biologics ADMA:US USD 17.75M 1.86M
Agenus AGEN:US USD 25.04M 6.93M
AstraZeneca AZN:LN USD 3.53B 174M
Astrazeneca AZN:US USD 3.53B 174M
Biocryst Pharmaceuticals BCRX:US USD 50.15M 13.23M
Dynavax Technologies DVAX:US USD 30.38M 1.22M
Geron GERN:US USD 15.64M 8.2M
GlaxoSmithKline GSK:LN GBP 2.44B 467M
Mannkind MNKD:US USD 22.1M 543K
Merk MRK:US USD 2.63B 134M
Minerva Neurosciences NERV:US USD 1.88M 959.93K
Moderna Inc MRNA:US USD 375M 97M
Novartis NVS:US USD 3.7B 295M
Novavax NVAX:US USD 161.66M 38.79M
Pain Therapeutics PTIE:US USD 3.28M 466K
Peregrine Pharmaceuticals PPHM:US USD 7.11M 276K
Pfizer PFE:US USD 4.87B 1.33B
Sarepta Therapeutics SRPT:US USD 120.48M 15.69M
Tg Therapeutics TGTX:US USD 22.5M 8.25M